Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Engert A, et al. Among authors: diehl v. J Clin Oncol. 2010 May 1;28(13):2239-45. doi: 10.1200/JCO.2009.25.1835. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368566 Clinical Trial.
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Engert A, et al. Among authors: diehl v. J Clin Oncol. 2003 Oct 1;21(19):3601-8. doi: 10.1200/JCO.2003.03.023. Epub 2003 Aug 11. J Clin Oncol. 2003. PMID: 12913100 Clinical Trial.
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Bredenfeld H, et al. Among authors: diehl v. J Clin Oncol. 2004 Jun 15;22(12):2424-9. doi: 10.1200/JCO.2004.09.114. Epub 2004 May 10. J Clin Oncol. 2004. PMID: 15136597 Clinical Trial.
First-line treatment of Hodgkin's lymphoma.
Klimm B, Engert A, Diehl V. Klimm B, et al. Among authors: diehl v. Curr Hematol Rep. 2005 Jan;4(1):15-22. Curr Hematol Rep. 2005. PMID: 15610655 Review.
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A, Haverkamp H, Engert A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V, Josting A. Shimabukuro-Vornhagen A, et al. Among authors: diehl v. J Clin Oncol. 2005 Aug 20;23(24):5739-45. doi: 10.1200/JCO.2005.17.970. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009944
840 results